



# Patient Report


Specimen ID: 268-059-0949-0  
Control ID: 41249429399

Acct # [REDACTED]

Phone: (813) 445-7342

Rte: 00

Defy Medical, LLC  
4809 N Armenia Ave Ste 220  
Tampa FL 33603



## Patient Details

DOB: 05/13/1964  
Age(y/m/d): 056/04/11  
Gender: M  
Patient ID:

## Specimen Details

Date collected: 09/24/2020 0752 Local  
Date received: 09/24/2020  
Date entered: 09/24/2020  
Date reported: 10/03/2020 0707 ET

## Physician Details

Ordering: [REDACTED]  
Referring:  
ID:  
NPI: 1093940041

## General Comments & Additional Information

Total Volume: Not Provided

Fasting: Yes

## Ordered Items

CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Testosterone, Free and Total; Dihydrotestosterone; DHEA, Serum; TSH; Prostate-Specific Ag, Serum; IGF-1; Estradiol, Sensitive; Sex Horm Binding Glob, Serum; Non LCA Req; Handwritten Order; Blood Drawing; Cardiovascular Report

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
CBC With Differential/Platelet					
WBC	5.9		x10E3/uL	3.4-10.8	01
RBC	5.49		x10E6/uL	4.14-5.80	01
Hemoglobin	17.7		g/dL	13.0-17.7	01
Hematocrit	52.0	High	%	37.5-51.0	01
MCV	95		fL	79-97	01
MCH	32.2		pg	26.6-33.0	01
MCHC	34.0		g/dL	31.5-35.7	01
RDW	12.8		%	11.6-15.4	01
Platelets	166		x10E3/uL	150-450	01
Neutrophils	56		%	Not Estab.	01
Lymphs	27		%	Not Estab.	01
Monocytes	11		%	Not Estab.	01
Eos	5		%	Not Estab.	01
Basos	1		%	Not Estab.	01
Neutrophils (Absolute)	3.3		x10E3/uL	1.4-7.0	01
Lymphs (Absolute)	1.6		x10E3/uL	0.7-3.1	01
Monocytes (Absolute)	0.7		x10E3/uL	0.1-0.9	01
Eos (Absolute)	0.3		x10E3/uL	0.0-0.4	01
Baso (Absolute)	0.1		x10E3/uL	0.0-0.2	01
Immature Granulocytes	0		%	Not Estab.	01
Immature Grans (Abs)	0.0		x10E3/uL	0.0-0.1	01
Comp. Metabolic Panel (14)					
Glucose	97		mg/dL	65-99	01
BUN	13		mg/dL	6-24	01
Creatinine	0.88		mg/dL	0.76-1.27	01
eGFR If NonAfricn Am	96		mL/min/1.73	>59	
eGFR If Africn Am	111		mL/min/1.73	>59	

Date Issued: 10/03/20 0711 ET

## FINAL REPORT

Page 1 of 3

This document contains private and confidential health information protected by state and federal law.  
If you have received this document in error, please call 205-581-3500

© 1995-2020 Laboratory Corporation of America® Holdings  
All Rights Reserved - Enterprise Report Version: 1.00

Patient: **DAVE MANTON**  
 DOB: 05/13/1964

Patient ID:

Control ID: **4-230120392**

Specimen ID: 268-059-0949-0  
 Date collected: 09/24/2020 0752 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
BUN/Creatinine Ratio	15			9-20	
Sodium	139		mmol/L	134-144	01
Potassium	4.7		mmol/L	3.5-5.2	01
Chloride	102		mmol/L	96-106	01
Carbon Dioxide, Total	25		mmol/L	20-29	01
Calcium	9.7		mg/dL	8.7-10.2	01
Protein, Total	6.7		g/dL	6.0-8.5	01
Albumin	4.5		g/dL	3.8-4.9	01
Globulin, Total	2.2		g/dL	1.5-4.5	
A/G Ratio	2.0			1.2-2.2	
Bilirubin, Total	0.9		mg/dL	0.0-1.2	01
Alkaline Phosphatase	60		IU/L	39-117	01
AST (SGOT)	41	High	IU/L	0-40	01
ALT (SGPT)	85	High	IU/L	0-44	01
<b>Lipid Panel</b>					
Cholesterol, Total	97	Low	mg/dL	100-199	01
Triglycerides	116		mg/dL	0-149	01
HDL Cholesterol	45		mg/dL	>39	01
VLDL Cholesterol Cal	21		mg/dL	5-40	
LDL Chol Calc (NIH)	31		mg/dL	0-99	
<b>Testosterone, Free and Total</b>					
Testosterone, Serum	747		ng/dL	264-916	01
Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.					
Free Testosterone(Direct)	26.8	High	pg/mL	7.2-24.0	02
Dihydrotestosterone	66		ng/dL		03
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. Reference Range: Adult Male: 30 - 85					
<b>DHEA, Serum</b>					
Dehydroepiandrosterone (DHEA) <sup>A</sup>	147		ng/dL	31-701	02
Age					
1 - 5 years 0 - 67					
6 - 7 years 0 - 110					
8 - 10 years 0 - 185					
11 - 12 years 0 - 201					
13 - 14 years 0 - 318					
15 - 16 years 39 - 481					
17 - 19 years 40 - 491					

Date Issued: 10/03/20 0711 ET

### FINAL REPORT

Page 2 of 3

This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 205-581-3500

© 1995-2020 Laboratory Corporation of America® Holdings  
 All Rights Reserved - Enterprise Report Version: 1.00



Patient: [REDACTED]  
 DOB: [REDACTED]

Patient ID:

Control ID: [REDACTED]

 Specimen ID: 268-059-0949-0  
 Date collected: 09/24/2020 0752 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
			>19 years	31 - 701		
<b>TSH</b>	1.530		uIU/mL	0.450-4.500		01
<b>Prostate-Specific Ag, Serum</b>						
Prostate Specific Ag, Serum	2.1		ng/mL	0.0-4.0		01
Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.						
<b>IGF-1</b>						
Insulin-Like Growth Factor I	112		ng/mL	68-247		02
<b>Estradiol, Sensitive</b>	19.2		pg/mL	8.0-35.0		02
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration. Methodology: Liquid chromatography tandem mass spectrometry (LC/MS/MS)						
<b>Sex Horm Binding Glob, Serum</b>	13.1	Low	nmol/L	19.3-76.4		01
<b>Cardiovascular Report</b>						
Interpretation	Note					04
Medical Director's Note: Test(s) 004102-Dehydroepiandrosterone (DHEA) was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. Supplemental report is available.						
PDF						04

**Comments:**

A This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

01	MB	LabCorp Birmingham	Dir: Brian Ragland, MD
02	BN	1801 First Avenue South, Birmingham, AL 35233-1935	
03	ES	LabCorp Burlington	Dir: Sanjai Nagendra, MD
		1447 York Court, Burlington, NC 27215-3361	
04	LITIL	Esoterix Inc	Dir: Samuel Pepkowitz, MD
		4301 Lost Hills Road, Calabasas Hills, CA 91301-5358	
		Litholink Corporation	Dir: John Asplin, MD
		150 Spring Lake Dr Ste A, Itasca, IL 60143-2091	

For inquiries, the physician may contact Branch: 800-877-5227 Lab: 205-581-3500